We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-12.71%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$1.09B
AUM Growth
+$188M
Cap. Flow
+$375M
Cap. Flow %
34.46%
Top 10 Hldgs %
59.52%
Holding
48
New
18
Increased
11
Reduced
4
Closed
7

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$52M
2
PEN icon
Penumbra
PEN
+$46.4M
3
UTHR icon
United Therapeutics
UTHR
+$37.9M
4
ZYME icon
Zymeworks
ZYME
+$35.1M
5
DXCM icon
DexCom
DXCM
+$23.5M

Top Sells

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$28M
2
ASND icon
Ascendis Pharma A/S
ASND
+$22.3M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$15.3M
4
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$5.02M
5
RVLP
RVL Pharmaceuticals plc Ordinary Shares
RVLP
+$3.52M

Sector Composition

Rank Sector Weight
1 Healthcare 85.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GNFT
26
DELISTED
Genfit
GNFT
$11.9M 1.1%
685,553
-8,700
-1% -$152K
ZGNX
27
CALL
DELISTED
Zogenix, Inc.
ZGNX
$10M 0.92%
+250,000
New +$11.5M
ALLK
28
DELISTED
Allakos
ALLK
$9.83M 0.9%
+125,000
New +$8.25M
SILK
29
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$9.82M 0.9%
+301,979
New +$12M
TPST icon
30
Tempest Therapeutics
TPST
$13.7M
$9.16M 0.84%
6,606
– –
TPTX
31
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$8.36M 0.77%
+222,222
New +$9.67M
YARW
32
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
$7.4M 0.68%
459
-23
-5% -$371K
ABEO icon
33
Abeona Therapeutics
ABEO
$366M
$7.31M 0.67%
+129,424
New +$9.69M
ATRA icon
34
Atara Biotherapeutics
ATRA
$75.5M
$7.06M 0.65%
+20,000
New +$7.46M
EXEL icon
35
Exelixis
EXEL
$13.3B
$5.48M 0.5%
+309,700
New +$6.27M
AXSM icon
36
CALL
Axsome Therapeutics
AXSM
$11.2B
$4.05M 0.37%
+200,000
New +$5.14M
IOVA icon
37
CALL
Iovance Biotherapeutics
IOVA
$1.82B
$3.64M 0.33%
200,000
– –
KA
38
DELISTED
Kineta, Inc. Common Stock
KA
$2.96M 0.27%
25,000
– –
MYOV
39
DELISTED
Myovant Sciences Ltd.
MYOV
$1.69M 0.16%
+325,000
New +$2.41M
OPK icon
40
Opko Health
OPK
$985M
$193K 0.02%
+92,140
New +$188K
STRM
41
DELISTED
Streamline Health Solutions
STRM
$141K 0.01%
8,676
– –
LRMR icon
42
Larimar Therapeutics
LRMR
$397M
– –
-184,266
Closed -$2.63M
RVLP
43
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
– –
-926,933
Closed -$3.52M
FPRX
44
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-547,712
Closed -$3.3M
FOMX
45
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-2,110,071
Closed -$5.02M
ZGNX
46
PUT
DELISTED
Zogenix, Inc.
ZGNX
– –
-300,000
Closed -$14.3M
BHVN
47
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-350,000
Closed -$15.3M
BHVN
48
PUT
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-200,000
Closed -$8.76M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q3 2019 Portfolio in Review

As of Q3 2019, Great Point Partners held 48 positions worth $1.09B, up 21% from $901M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Great Point Partners deployed $375M of net new capital in Q3 2019, opening 18 new positions and adding to 11 existing holdings. Its largest new stake was Nektar Therapeutics: 141,667 shares worth $38.7M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 90% a quarter earlier.

On the sell side, the largest reduction was Tricida, Inc. Common Stock, an estimated $28M trimmed.

  • Great Point Partners's largest Q3 2019 buy was Nektar Therapeutics: 141,667 shares worth $38.7M.
  • Great Point Partners added most to Zymeworks in Q3 2019, an estimated $35.1M increase.
  • Great Point Partners's biggest Q3 2019 reduction was Tricida, Inc. Common Stock, cutting an estimated $28M.
  • Great Point Partners fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q3 2019, selling an estimated $15.3M.
  • Great Point Partners's ten largest holdings make up 60% of its $1.09B portfolio in Q3 2019.
  • Great Point Partners opened 18 new positions and closed 7 in Q3 2019.
  • Great Point Partners's portfolio value rose 21% quarter-over-quarter to $1.09B.

Based on Great Point Partners's 13F filing for Q3 2019, filed 15 Nov 2019.